Medicenna Therapeutics Corp - Asset Resilience Ratio

Latest as of December 2025: 81.24%

Medicenna Therapeutics Corp (MDNA) has an Asset Resilience Ratio of 81.24% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CA$10.61 Million

≈ $7.68 Million USD Cash + Short-term Investments

Total Assets

CA$13.06 Million

≈ $9.45 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2017–2025)

This chart shows how Medicenna Therapeutics Corp's Asset Resilience Ratio has changed over time. Check strategic asset allocation of Medicenna Therapeutics Corp to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Medicenna Therapeutics Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Medicenna Therapeutics Corp.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CA$10.61 Million	81.24%
Short-term Investments	CA$0.00	0%
Total Liquid Assets	CA$10.61 Million	81.24%

Asset Resilience Insights

Very High Liquidity: Medicenna Therapeutics Corp maintains exceptional liquid asset reserves at 81.24% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Medicenna Therapeutics Corp Industry Peers by Asset Resilience Ratio

Compare Medicenna Therapeutics Corp's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Tubize-Fin BR:TUB	Biotechnology	0.05%
Verona Pharma plc F:I9SA	Biotechnology	0.00%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
Syndax Pharmaceuticals Inc NASDAQ:SNDX	Biotechnology	46.79%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Vor Biopharma Inc NASDAQ:VOR	Biotechnology	63.47%
Chengdu Kanghua Biological Products SHE:300841	Biotechnology	1.19%
Jiangsu Aidea Pharmaceutical Co Ltd SHG:688488	Biotechnology	4.35%

Annual Asset Resilience Ratio for Medicenna Therapeutics Corp (2017–2025)

The table below shows the annual Asset Resilience Ratio data for Medicenna Therapeutics Corp.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-03-31	87.51%	CA$24.84 Million ≈ $17.97 Million	CA$28.38 Million ≈ $20.53 Million	-1.24pp
2024-03-31	88.75%	CA$16.98 Million ≈ $12.28 Million	CA$19.13 Million ≈ $13.84 Million	-3.43pp
2023-03-31	92.18%	CA$33.60 Million ≈ $24.30 Million	CA$36.45 Million ≈ $26.36 Million	+4.63pp
2022-03-31	87.55%	CA$20.54 Million ≈ $14.85 Million	CA$23.46 Million ≈ $16.97 Million	-8.03pp
2021-03-31	95.58%	CA$40.38 Million ≈ $29.21 Million	CA$42.25 Million ≈ $30.56 Million	-3.64pp
2020-03-31	99.22%	CA$37.70 Million ≈ $27.27 Million	CA$38.00 Million ≈ $27.49 Million	+53.51pp
2019-03-31	45.71%	CA$2.37 Million ≈ $1.72 Million	CA$5.19 Million ≈ $3.75 Million	-44.33pp
2018-03-31	90.04%	CA$3.94 Million ≈ $2.85 Million	CA$4.37 Million ≈ $3.16 Million	-6.89pp
2017-03-31	96.93%	CA$14.04 Million ≈ $10.15 Million	CA$14.48 Million ≈ $10.48 Million	--

pp = percentage points

About Medicenna Therapeutics Corp

TO:MDNA Canada Biotechnology

Market Cap

$21.72 Million

CA$30.03 Million CAD

Market Cap Rank

#24791 Global

#954 in Canada

Share Price

CA$0.36

Change (1 day)

+2.86%

52-Week Range

CA$0.35 - CA$1.64

All Time High

CA$7.00